First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00455936

Recruitment Status : Completed

First Posted : April 4, 2007

Last Update Posted : October 25, 2010

Sponsor:

Collaborator:

AstraZeneca

Information provided by:

National Cancer Center, Korea

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	November 2009
Actual Study Completion Date :	March 2010

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Lee Y, Kim SH, Han JY, Kim HT, Yun T, Lee JS. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. J Cancer Res Clin Oncol. 2012 Dec;138(12):2009-16. doi: 10.1007/s00432-012-1281-4. Epub 2012 Jul 7.

To Top